Gossamer Bio Inc. (NASDAQ: GOSS)
$1.24
+0.0600 ( +5.08% ) 4.3M
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Market Data
Open
$1.24
Previous close
$1.18
Volume
4.3M
Market cap
$282.77M
Day range
$1.18 - $1.33
52 week range
$0.45 - $1.88
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 66 | May 07, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
8-k | 8K-related | 15 | May 06, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 19 | Apr 24, 2024 |
4 | Insider transactions | 1 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |